Mount Sinai Researchers Publish New Edition of Psychiatry "Bible"
In light of the accelerated pace of discovery in understanding psychiatric illnesses, experts from Mount Sinai have published the 4th edition of Neurobiology of Mental Illness.
In light of the accelerated pace of discovery in understanding psychiatric illnesses, experts from the Icahn School of Medicine at Mount Sinai have published the fourth edition of Neurobiology of Mental Illness (Oxford University Press), a hallmark textbook in the field of psychiatry.
Edited by Dennis S. Charney, MD; Joseph D. Buxbaum, PhD; Pamela Sklar, MD, PhD; and Eric J. Nestler, MD, PhD, all of the Icahn School of Medicine at Mount Sinai, the text highlights new methodologies, diagnostic classifications, and clinical breakthroughs in psychiatric illness. With 32 new chapters, the text includes new highlights in psychiatric genomics, a groundbreaking field showing important promise in helping to address the neurobiological mechanisms behind mental illness. Released in parallel with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the textbook provides valuable perspective and insight on the changing landscape of psychiatric diagnosis and treatment.
“Psychiatry and Neuroscience are fields that are evolving at a rapid rate, with the emergence of psychiatric genomics, novel imaging techniques, and new drugs and drug targets resulting from these discoveries,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai and Executive Vice President for Academic Affairs, The Mount Sinai Medical Center. “We hope that the essential updates we have made to this text will be valuable to psychiatry residents, psychiatric researchers, and doctoral students in the neurosciences and genetics.”
Dilip V. Jeste, MD, Distinguished Professor of Psychiatry and Neurosciences at the University of California at San Diego and 2012 President of the American Psychiatric Association, said, “As psychiatric diagnoses continue to be hotly debated, the Fourth Edition of this mainstay volume reminds the field of our deeper understanding of the neurobiological underpinnings of the brain, just a decade after the first Edition was published. This completely revamped Edition highlights articles by leaders in the fields of psychiatry and neurosciences and offers intelligent insights into how neuroscience may impact how we will diagnose and treat individuals suffering from mental illness in the very near future. The book continues to be a tour de force.”
Dennis Charney, MD, is a world expert in the neurobiology and treatment of mood and anxiety disorders. He has made fundamental contributions to the understanding of the causes of human anxiety, fear and depression and the discovery of new treatments for mood and anxiety disorders. More recently, his pioneering research has expanded to include the psychobiological mechanisms of human resilience to stress. Dr. Charney’s work in depression has led to new hypotheses regarding the mechanisms of antidepressant drugs and discovery of new and novel therapies for treatment-resistant depression including lithium and ketamine. The work demonstrating that ketamine is a rapidly acting antidepressant has been hailed as one of the most exciting developments in antidepressant therapy in more than half a century. Dr. Charney is a member of the Institute of Medicine.
Joseph D. Buxbaum, PhD, is the G. Harold and Leila Y. Mathers Professor of Psychiatry, Genetics and Genomic Sciences, and Neuroscience, and the Director of the Seaver Autism Center at Mount Sinai. He has focused on understanding the molecular and genetic basis of autism spectrum conditions, which will allow for a better understanding of what causes them, leading to the development of novel therapeutics for these disorders. Dr. Buxbaum is a lead investigator in the Autism Genome Project. Dr. Buxbaum is the founder and co-leader of the Autism Sequencing Consortium, an international group of scientists studying the genome of thousands of autism patients, in order to accelerate our understanding of the causes and treatments of autism.
Pamela Sklar, MD, PhD, is Chief of the Division of Psychiatric Genomics, and Professor of Psychiatry, Neuroscience, Genetics and Genomic Sciences at Mount Sinai. Dr. Sklar is a neuroscientist, human geneticist, and clinical psychiatrist investigating the genetic causes of psychiatric disorders, including schizophrenia and bipolar disorder. A major focus of her work has been to identify susceptibility genes for psychiatric diseases by applying tools developed for understanding and characterizing human sequence variation. Dr. Sklar has long been involved in leadership positions for several consortia focusing on large-scale genomic studies including the International Schizophrenia Consortium and the Psychiatric Genomics Consortium.
Eric J. Nestler, MD, PhD, is the Nash Family Professor and Chair of Neuroscience and Director of the Friedman Brain Instituteat Mount Sinai. His laboratory studies the molecular and cellular changes that occur in regions of the brain important for reward, motivation, and emotions in response to chronic administration of a drug of abuse or chronic exposure to stress in animal models. The goal of Dr. Nestler’s research is to better understand the molecular mechanisms of addiction and depression based on work in animal models, and to use this information to develop improved treatments of these disorders. Dr. Nestler is a member of the Institute of Medicine and of the American Academy of Arts and Sciences.
To learn more about Neurobiology of Mental Illness, visit http://icahn.mssm.edu/education/masters/public-health/graduate.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.